J
Julia Hutter
Researcher at National Institutes of Health
Publications - 9
Citations - 312
Julia Hutter is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Vaccination & Vaccine efficacy. The author has an hindex of 3, co-authored 5 publications receiving 200 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H. Barouch,Dan H. Barouch,Frank Tomaka,Frank Wegmann,Daniel J. Stieh,Galit Alter,Merlin L. Robb,Merlin L. Robb,Nelson L. Michael,Lauren Peter,Joseph P. Nkolola,Erica N. Borducchi,Abishek Chandrashekar,David Jetton,Kathryn E. Stephenson,Kathryn E. Stephenson,Wenjun Li,Bette T. Korber,Georgia D. Tomaras,David C. Montefiori,Glenda Gray,Nicole Frahm,M. Juliana McElrath,Lindsey R. Baden,Jennifer Johnson,Julia Hutter,Edith Swann,Etienne Karita,Hannah Kibuuka,Juliet Mpendo,Nigel Garrett,Kathy Mngadi,Kundai Chinyenze,Frances Priddy,Erica Lazarus,Fatima Laher,Sorachai Nitayapan,Punnee Pitisuttithum,Stephan Bart,Thomas B. Campbell,Robert Feldman,Gregg Lucksinger,Caroline Borremans,Katleen Callewaert,Raphaele Roten,Jerald C. Sadoff,Lorenz Scheppler,Mo Weijtens,Karin Feddes-de Boer,Danielle van Manen,Jessica Vreugdenhil,Roland Zahn,Ludo Lavreys,Steven Nijs,Jeroen Tolboom,Jenny Hendriks,Zelda Euler,Maria G. Pau,Hanneke Schuitemaker +58 more
TL;DR: All vaccine regimens demonstrated favourable safety and tolerability and immunogenicity and protective efficacy against a series of six repetitive, heterologous, intrarectal challenges with a rhesus peripheral blood mononuclear cell-derived challenge stock of simian-human immunodeficiency virus (SHIV-SF162P3).
Journal ArticleDOI
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa.
Linda-Gail Bekker,One B. Dintwe,Andrew Fiore-Gartland,Keren Middelkoop,Julia Hutter,Anthony Williams,April K. Randhawa,Morten Ruhwald,Morten Ruhwald,Ingrid Kromann,Peter Andersen,Carlos A. DiazGranados,Kathryn Tucker Rutkowski,Dereck Tait,Maurine D. Miner,Erica Andersen-Nissen,Stephen C. De Rosa,Kelly E. Seaton,Georgia D. Tomaras,M. Juliana McElrath,Ann M. Ginsberg,James G. Kublin,Hvtn,Aeras A Protocol Team +23 more
TL;DR: Characterization of the assays and the immunogenicity of these vaccines may help to identify valuable markers of protection for upcoming immune correlates analyses of C-040-404 and future TB vaccine efficacy trials.
Journal ArticleDOI
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong,Yunda Huang,David Benkeser,Lindsay N. Carpp,Germán Añez,Wayne Woo,Alice McGarry,Lisa M. Dunkle,Iksung Cho,Christopher R. Houchens,Karen O. Martins,Lakshmi Jayashankar,Flora Castellino,Christos J. Petropoulos,Andrew Leith,Deanne Haugaard,Bill Webb,Yiwen Lu,Chenchen Yu,Bhavesh Borate,Lars van der Laan,Nima S. Hejazi,April Kaur Randhawa,Michele P. Andrasik,James G. Kublin,Julia Hutter,Maryam Keshtkar-Jahromi,Tatiana Beresnev,Lawrence Corey,Kathleen M. Neuzil,Dean Follmann,Julie A Ake,C. Gay,Karen L. Kotloff,Richard A. Koup,Ruben O. Donis,Peter B. Gilbert +36 more
TL;DR: In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), antiRBD binding IGC concentration (RBD IGC), and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose two are assessed as correlate of risk and as correlates of protection against COVID-19 as mentioned in this paper .
Journal ArticleDOI
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Mina C. Hosseinipour,Craig Innes,Sarita Naidoo,Philipp Mann,Julia Hutter,Gita Ramjee,Sebe M,Lucas Maganga,Michael E Herce,Allan C. deCamp,Kyle E. Marshall,One Dintwe,Erica Andersen-Nissen,Georgia D. Tomaras,Nonhlanhla N. Mkhize,Lynn Morris,Ryan L. Jensen,Miner,Giuseppe Pantaleo,S. Ding,Van Der Meeren O,Susan W. Barnett,MJ McElrath,Lawrence Corey,James G. Kublin +24 more
TL;DR: Both the prime/boost and coadministration regimens are safe and may be promising for advancement into efficacy trials depending on whether cellular or humoral responses are desired.
Posted ContentDOI
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Lisa M. Dunkle,Karen L. Kotloff,Germán Añez,Jeffrey M. Adelglass,Alejandro Q. Barrat Hernandez,Wayne L. Harper,Daniel M. Duncanson,Monica A. McArthur,Diana F. Florescu,Scott McClelland,Veronica Garcia-Fragoso,Robert A. Riesenberg,David B. Musante,David L. Fried,Beth E. Safirstein,Mark McKenzie,Robert Jeanfreau,Jeffrey K. Kingsley,Jeffrey A. Henderson,Dakotah C. Lane,Guillermo M. Ruiz-Palacios,Lawrence Corey,Kathleen M. Neuzil,Robert W. Coombs,Alexander L. Greninger,Julia Hutter,Julie A Ake,Katherine Smith,Wayne Woo,Iksung Cho,Gregory M. Glenn,Filip Dubovsky +31 more
TL;DR: In this article, an adjuvanted, recombinant S protein nanoparticle vaccine that demonstrated clinical efficacy for prevention of Covid-19 in phase 2b/3 trials in the United Kingdom and South Africa was presented.